TABLE 2.

Range of recommendations for management of screen-detected lung nodules

	Routine annual or biennial repeat screening	Early recall (repeat LDCT 1–6 months)	Diagnostic workup
Baseline screening
Solid nodule	No nodule or nodule <5 mm or PanCan risk score¶ <6%	>5 mm to <15 mm; or ≥100 mm3 to <500 mm3; or PanCan risk score¶ ≥6 to <30	≥15 mm or ≥500 mm3 or PanCan risk score¶ ≥30
Part-solid nodule#	<6 mm	≥6 mm to <8 mm	≥8 mm or ≥268 mm3
Nonsolid nodule	<6 mm	6 to <15 mm	≥15 mm persistent in 3 months or develop solid component
Annual/biennial repeat screening
New solid nodule	<4 mm	4 mm to <8 mm or ≥50 mm3 to <200 mm3	≥8 mm or ≥200 mm3
Pre-existing solid nodule	VDT >600 days	VDT 400 to 600 days	VDT <400 days
Part-solid nodule#	<6 mm	≥6 mm to <8 mm	≥8 mm
Nonsolid nodules	<15 mm	≥15 mm	Development of solid component ≥6 mm or become solid

LDCT: low-dose computed tomography; PanCan: Pan-Canadian Early Detection of Lung Cancer Study; VDT: volume doubling time. ^#: refers to size of solid component; ^¶: nodule malignancy risk score [24, 86]. Data from [22, 24, 78–91].